Coombe Bender & Co LLC Takes $334,000 Position in Pfizer Inc. (NYSE:PFE)

Coombe Bender & Co LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,584 shares of the biopharmaceutical company’s stock, valued at approximately $334,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Trifecta Capital Advisors LLC grew its holdings in shares of Pfizer by 3.7% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 325 shares during the period. Confluence Wealth Services Inc. boosted its holdings in shares of Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after purchasing an additional 342 shares during the last quarter. Carr Financial Group Corp boosted its holdings in shares of Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 355 shares during the last quarter. Caldwell Sutter Capital Inc. boosted its holdings in shares of Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after purchasing an additional 364 shares during the last quarter. Finally, Lafayette Investments Inc. boosted its holdings in shares of Pfizer by 2.2% during the third quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 368 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE traded up $0.70 during mid-day trading on Thursday, reaching $27.88. 32,050,252 shares of the company’s stock traded hands, compared to its average volume of 42,426,480. The business’s 50-day moving average price is $26.87 and its 200-day moving average price is $28.25. The stock has a market capitalization of $157.87 billion, a P/E ratio of 76.89, a price-to-earnings-growth ratio of 1.15 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the company earned $1.23 earnings per share. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.03%. Pfizer’s payout ratio is 466.67%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $36.53.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.